Welcome
Support Centre
11 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
SIOPEL-3 Liver Tumour Studies: Hepatoblastoma and hepatocellular carcinoma
Source of recordUK Trials
ISRCTNISRCTN87675276
Date ISRCTN assigned01/07/2001
Local reference number(s)LT1998/01
Public titleSIOPEL-3 Liver Tumour Studies: Hepatoblastoma and hepatocellular carcinoma
Scientific title
AcronymNot Applicable
Disease/condition/study domainLiver
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Diagnosis is hepatoblastoma
2. Pretext is I, II or III
3. No extrahepatic Involvement
4. Age <16 at diagnosis
5. No prior treatment
6. No primary surgery required
7. Lung CT scan performed
8. Initial serum alpha-feta protein value obtained (greater than or 100 ng/ml)
Participants - exclusion criteriaPretext 4, extra hepatic disease, lung metastases, tumour rupture.
Patient information material
Anticipated start date01/06/1998
Anticipated end date31/12/2005
Status of trialCompleted
Target number of participants500+
InterventionsStandard risk hepatoblastoma

Arm 1:
Initial Treatment - 1 course cisplatin. Continuation treatment - 5 courses cisplatin/doxorubicin.
Surgery after course 3 (if feasible).

Arm 2:
Initial treatment - 1 course cisplatin. Continuation treatment - 5 courses cisplatin.
Surgery after course 3 (if feasible).
Primary outcome measure(s)Complete resection
Secondary outcome measure(s)Toxicity measures, survival and event free survival
Trial websitehttp://www.siopel.org/
Sources of fundingCancer Research UK
Sponsor nameUniversity Hospitals of Leicester NHS Trust (UK)
Sponsor detailsTrust Headquarters
Gwendolen House
Gwendolen Road
Leicester
United Kingdom
LE5 4QF
Contact nameDr Penelope Brock
Contact detailsGreat Ormond Street Hospital
Great Ormond Street
London
United Kingdom
WC1N 3JN
Contact telephone+44 (0) 20 7405 9200
Contact fax+44 (0) 20 7813 8588
Contact emailbrockp@gosh.nhs.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN87675276
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central